Antiplatelet therapy beyond 2012: Role of personalized medicine

Udaya S. Tantry, Andrzej Budaj, Paul A. Gurbel

Research output: Contribution to journalReview articlepeer-review


Since its first approval in 1997, clopidogrel has revolutionized interventional cardiology and transformed therapy for non-ST-segment elevation myocardial infarction (NSTEMI), STEMI, and percutaneous coronary intervention-treated patients. It enjoyed a remarkable 15-year "homerun" in the world market without any major competition. With the introduction of more potent P2Y12 receptor blockers, the current antiplatelet strategy is undergoing a transition period. Generic clopidogrel is inexpensive and pharmacodynamically effective in at least two thirds of the patients with coronary artery disease. The unpredictable, slow onset, and overall modest pharmacodynamic effects are the major limitations of clopidogrel. The new, more potent P2Y12 receptor blockers overcome the limitations of clopidogrel therapy and are associated with better clinical efficacy, but are more costly and associated with more bleeding. In this scenario, personalization of antiplatelet therapy based on platelet function and genetic testings to strike a balance between cost, benefit, and safety is a potential option. Copyright by Medycyna Praktyczna, 2012.

Original languageEnglish (US)
Pages (from-to)298-305
Number of pages8
JournalPolskie Archiwum Medycyny Wewnetrznej
Issue number6
StatePublished - 2012


  • Antiplatelet therapy
  • Clopidogrel
  • Prasugrel
  • Ticagrelor

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Antiplatelet therapy beyond 2012: Role of personalized medicine'. Together they form a unique fingerprint.

Cite this